Dual drug combo helps patients with previously untreated follicular lymphomaJune 9th, 2008 - 4:56 pm ICT by ANI
Washington , June 9 (ANI): A study by the Cancer and Leukemia Group B (CALGB) revealed that galiximab, an investigational anti-CD80 monoclonal antibody, when given in combination with rituximab, showed beneficial results in the treatment of patients with previously untreated follicular lymphoma.
In a phase II clinical trial, the study conducted on 61 patients, showed that 70 percent of patients with previously untreated follicular lymphoma responded to treatment with galiximab. While 44 percent achieved a complete response, 26 percent of the participants had a partial response.
The results indicated that adding galiximab to rituximab may be a promising regimen for patients with follicular lymphoma (FL), a common type of non-Hodgkin lymphoma (NHL), and that further study is warranted.
The study was aimed at determining the overall response rate (ORR) and time-to-progression of the disease after treatment with a combined regimen of galiximab and rituximab. However, at this point, it is too early to assess the time-to-progression endpoint.
“Most non-Hodgkin lymphoma patients receive rituximab, either as a single agent or in combination with chemotherapy. Now, ‘biologic’ agents are being studied in combination to assess the efficacy of dual antibody therapies as potential alternatives to chemotherapy-based regimens,” said Myron Czuczman, M.D., Roswell Park Cancer Institute, principal investigator of this study.
Those who enrolled in the study had been diagnosed with CD20-positive FL but had not received treatment for the disease. Study patients were given galiximab plus rituximab together once a week for four weeks and then every two months for the next eight months. This “extended induction” schedule was chosen based on results from an earlier Swiss (SAKK) trial using the same schedule with single-agent rituximab.
It was found that 13 percent of patients reported a grade 3 adverse event; no grade 4 toxicities were associated with this combination immunotherapy regimen.
Galiximab is an anti-CD80 monoclonal antibody that has been studied as a single-agent in previously treated FL and in combination with rituximab against relapsed FL.
The CD80 molecule is found on the surface of activated macrophages, dendritic cells and cells from various subtypes of NHL. Galiximab’s potential mechanisms of action include Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and possible immunomodulatory effects on host effector cells affecting the tumor microenvironment.
The study was presented at the 10th International Conference on Malignant Lymphoma (ICML). (ANI)
Tags: antibody therapies, beneficial results, biologic agents, calgb, follicular lymphoma, further study, galiximab, grade 3, leukemia group, lymphoma, lymphoma patients, non hodgkin lymphoma, park cancer institute, partial response, principal investigator, regimens, response rate, roswell park cancer, roswell park cancer institute, study patients